0K9E Stock Chart & Stats
$161.25
$3.31(2.12%)
At close: 4:00 PM EDT
$161.25
$3.31(2.12%)
Day’s Range― - ―
52-Week Range$122.08 - $170.29
Previous CloseN/A
Volume62.00
Average Volume (3M)5.61K
Market Cap
$295.08B
Enterprise Value$311.27B
Total Cash (Recent Filing)$8.97B
Total Debt (Recent Filing)$48.31B
Price to Earnings (P/E)30.9
Beta1.01
Next Earnings
Feb 03, 2027EPS Estimate
2.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.25
Shares Outstanding2,034,819,500
10 Day Avg. Volume816
30 Day Avg. Volume5,608
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)5.79
Price to Sales (P/S)4.88
P/FCF Ratio15.11
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue5.53
Enterprise Value/Gross Profit7.41
Enterprise Value/Ebitda14.29
Forecast
1Y Price Target
$159.67Price Target Upside-0.98% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)8.81
Revenue Forecast (FY)$57.21B
Bulls Say, Bears Say
Bulls Say
Growth Portfolio MomentumStrong growth across multiple priority brands shows that Novartis has several commercially advancing products rather than relying on one medicine. Broad momentum across oncology, immunology, neuroscience and cardiovascular therapies supports durable revenue replacement as older products face erosion.
High-margin Operating ModelThe combination of core profit growth, a 41.6% margin and lower SG&A indicates meaningful operating leverage in the business. Continued productivity can help fund research and launches while preserving profitability as Novartis expands its innovation portfolio.
Robust Cash GenerationLarge free-cash-flow generation gives Novartis internal funding for clinical development, business development, dividends and repurchases. This financial capacity strengthens the company’s ability to sustain investment in new medicines through normal pipeline volatility.
Bears Say
Higher Financial LeverageThe sharp increase in debt relative to equity reduces balance-sheet flexibility and makes the company more sensitive to earnings volatility and financing costs. Higher leverage can constrain capital allocation if pipeline spending or commercial performance weakens.
Patent And Competitive ErosionGeneric and biosimilar competition can structurally reduce sales and profitability when exclusivity expires, requiring new launches to replace lost revenue. Entresto and Xolair pressure therefore creates an ongoing offset to growth and complicates margin expansion.
Pipeline Execution SetbacksMultiple late-stage setbacks increase uncertainty around the pipeline’s ability to replenish future growth and reduce the return on prior development investment. The Rhapsido pause also delays a potential expansion, while failed trials can raise future R&D demands.
Novartis News
0K9E FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest share price was $122.08 and its highest was $170.29 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is $295.08B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Feb 03, 2027 which is in 95 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Oct 27, 2026. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.271 by $0.189.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Overvalued.
Does Novartis Ag pay dividends?
Novartis Ag does not currently pay dividends.
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 2.24.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,034,819,500 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of $2.46 in its last earnings report, beating expectations of $2.271. Following the earnings report the stock price went up 0.88%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in GB:0K9E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novartis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$159.67 (-0.98% Downside)
$159.67 (-0.98% Downside)
Blogger Sentiment
Bullish
GB:0K9E Sentiment 61%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
34.85%
12-Months-Change
Fundamentals
Return on Equity
24.24%
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novartis Ag
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
0K9E Company Deck
0K9E Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive, supported by 4% quarterly sales growth, 10% core operating income growth, 29% priority-brand growth, strong performance from key brands, positive remibrutinib data, multiple regulatory milestones and an upgrade to full-year core operating income guidance. However, reported earnings and nine-month results were weaker, while delgociptacine and pelacarsen had unsuccessful Phase 3 outcomes, Rhapsido autoimmune studies remain on hold, and generic and biosimilar pressures are expected to affect future performance. Highlights significantly outweighed the explicitly stated challenges.View all GB:0K9E earnings summaries0K9E Stock 12 Month Forecast
Average Price Target
$159.67
▼(-0.98% Downside)